Laretol 1mcg Injection contains Calcitriol, the active form of vitamin D3, at a concentration of 1 microgram per dose. It is primarily indicated for the management of conditions associated with hypocalcemia, such as hypoparathyroidism and renal osteodystrophy in patients with chronic renal failure. Calcitriol plays a crucial role in calcium homeostasis by enhancing intestinal absorption of calcium and phosphate, thereby facilitating normal bone mineralization. This injectable formulation allows for precise dosing in patients who may have impaired gastrointestinal absorption or require rapid correction of calcium levels. Laretol 1mcg Injection should be administered under strict medical supervision, with careful monitoring of serum calcium and phosphate levels to avoid hypercalcemia and hyperphosphatemia, which can lead to serious complications including nephrocalcinosis. Dosage adjustments should be individualized based on patient response and laboratory findings. Contraindications include hypercalcemia, vitamin D toxicity, and hypersensitivity to calcitriol or any excipients. Caution is advised in patients with cardiac arrhythmias or those receiving digitalis therapy. Laretol 1mcg Injection is a valuable therapeutic option in the management of disorders related to calcium metabolism, ensuring effective correction of calcium imbalance when oral therapy is inadequate or contraindicated.